期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

加强基因型分析发展个体化医学 被引量：5

原文传递
导出
摘要 疾病的诊断，从表型（phenotype）分析发展到表型和基因型（genotype）结合分析代表着医学的革命性进步。临床分子病理学，或称分子诊断，已成为当今迅猛兴起的病理亚学科之一。它从核酸水平（DNA和RNA）研究疾病发生和发展规律，揭示疾病时外源性基因在体内的存在和内源性基因的突变及表达异常，是传统形态病理学的有益补充和发展。
作者 吴秉铨 刘岩
机构地区 北京大学医学部病理学系
出处 《中华病理学杂志》 CAS CSCD 北大核心 2011年第10期651-654,共4页 Chinese Journal of Pathology
关键词 个体化医学 基因型分析 临床分子病理学 疾病发生 分子诊断 内源性基因 外源性基因 形态病理学
分类号 R450 [医药卫生—治疗学]
  • 相关文献

参考文献12

  • 1张治国,钟镐镐,孙桂芝,衡万杰,吴秉铨,韩跃飞.分子信标荧光探针检测结核分枝杆菌的临床应用[J].诊断学理论与实践,2006,5(4):312-314. 被引量：2
  • 2Gutiérrez J, Morales P, González MA, et al. Candida dubliniensis,a new fungal pathogen.J Basic Microbiol,2002,42(3):207-227.
  • 3Evans MF, Cooper K. Human papillomavirus integration:detection by in situ hybridization and potential clinical application.J Pathol,2004,202 (1):1-4.
  • 4周小鸽.EB病毒小RNA检测的临床病理学意义[J].中华病理学杂志,2006,35(6):321-323. 被引量：19
  • 5唐平,魏兵,杨雯娟,刘裔莎,步宏.乳腺癌预后/预测因子[J].中华病理学杂志,2011,40(2):73-76. 被引量：14
  • 6Hodi FS,Friedlander P,Corless CL,et al.Major response to imatinib mesylate in c-kit-mutated melanoma. J Clin Oncol,2008,26(12):2046-2051.
  • 7Satzger I,Küttler U,V(o)lker B,et al.Anal mucosal melanoma with c-kit-activating mutation and response to imatinib therapycase report and review of the literature.Dermatology,2010,220(1):77-81.
  • 8刘丛容,惠培.葡萄胎的分子诊断[J].中华病理学杂志,2011,40(1):6-10. 被引量：14
  • 9Vilar E,Gruber SB.Microsatellite instability in colorectal cancerthe stable evidence.Nat Rev Clin Oncol,2010,7(3):153-162.
  • 10Lasota J,Wasag B,Steigen SE,et al.Improved detection of c-kit exon 11 duplications in formalin-fixed, paraffin-embedded gastrointestinal stromal tumors.J Mol Diagn,2007,9(1):89-94.

二级参考文献113

  • 1高斌,刘敬忠.实时荧光PCR技术的研究及其应用进展[J].诊断学理论与实践,2005,4(6):507-509. 被引量：21
  • 2[6]Victor T,du Toit R,van Helden PD.Purification of sputum samples through sucrose improves detection of Mycobacterium tuberculosis by polymerase chain reaction[J].J Clin Microbiol,1992,30(6):1514-1517.
  • 3Hui P,Martel M,Parkash V.G estational trophoblastic diseases:recent advances in histopathologic diagnosis and related genetic aspects.Adv Anat Pathol,2005,12(3):116-125.
  • 4Berkowitz RS,Goldstein DP.Clinical practice.Molar pregnancy.N Engl J Med,2009,360(16):1639-1645.
  • 5Genest DR.Partial hydatidiform mole:clinicopathological features,differential diagnosis,ploidy and molecular studies,and gold standards for diagnosis.Int J Gynecol Pathol,2001,20(4):315-322.
  • 6Sebire NJ,Fisher RA,Foskett M,et al.Risk of recurrent hydatidiform mole and subsequent pregnancy outcome following complete or partial hydatidiform molar pregnancy.BJOG,2003,110(1):22-26.
  • 7Feltmate CM,Growdon WB,Wolfberg AJ,et al.Clinical characteristics of persistent gestational trophoblastic neoplasia after partial hydatidiform molar pregnancy.J Reprod Med,2006,51(11):902-906.
  • 8Fukunaga M,Katabuchi H,Nagasaka T,et al.Interobserver and intraobserver variability in the diagnosis of hydatidiform mole.Am J Surg Pathol,2005,29(7):942-947.
  • 9Howat AJ,Beck S,Fox H,et al.Can histopathologists reliably diagnose molar pregnancy? J Clin Pathol,1993,46(7):599.602.
  • 10Javey H,Borazjani G,Behmard S,et al.Discrepancies in the histological diagnosis of hydatidiform mole.Br J Obstet Gynaecol,1979,86(6):480-483.

共引文献45

同被引文献59

  • 1刘彤华.表皮生长因子受体家族与靶向性抗癌治疗[J].中华病理学杂志,2006,35(10):577-579. 被引量：21
  • 2潘明安.从病理科现状看医疗诊断之“短板”.健康报,2009-04-01(3).
  • 3Pirker R, Herth FJ, Kerr KM, et al. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol, 2010,5 (10) :1706-1713.
  • 4Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol, 2009, 27(26) :4247-4253.
  • 5Herpel E, Rocken C, Manke H, et al. Quality management and accreditation of research tissue banks: experience of the National Center for Tumor Diseases (NCT) Heidelberg. Virchows Arch, 2010, 457(6) :741-747.
  • 6Bevilacqua G, Bosman F, Dassesse T, et al. The role of the pathologist in tissue banking: European Consensus Expert Group Report. Virchows Arch, 2010, 456(4) :449-454.
  • 7Travis WD, Brambilla E, Muller-Hermelink HK, et al. Pathology and genetics of tumors of the lung, pleura, thymus and heat't. World Health Organization classifieation of tumours. Lyon: IARC Press, 2004.
  • 8Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med, 2005,353(2) :125-132.
  • 9Soda M, Choi YL, Enomoto M, et al. Identification of the transfbrming EMIA-ALK fusion gene in non-small-cell lung cancer. Nature,2007, 448(7153) :561-566.
  • 10Kwak EL, Camidge DR, Clark J, et al. Clinical activity observed in a phase I dose escalation trial of an oral c-met and ALK inhibitor, PF-02341066. J Clin Oncol, 2009,27 : 15s [ abstract 3509].

引证文献5

二级引证文献45

中华病理学杂志
2011年 第10期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部